<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2014-02-20 17:49:57Pharmaceutical industry Pharmacology National Multiple Sclerosis Society Medicine Health Autoimmune diseases Aaron E. Miller Corinne Goldsmith Dickinson Center for Multiple Sclerosis Multiple sclerosis Critical Path Institute Drug discovery |
Add to Reading List |
Contact: Arney Rosenblat National MS Society[removed]removed] Dianne Janis | The Critical Path to TB Drug Regimens Initiative Jan Gheuens, MD, PhD Global Health, Bill & Melinda Gates Foundation Addis Ababa, August 18th, 2010DocID: 1aMKd - View Document |
| PARTNERSHIPS T he Global Alliance for TB Drug Development (TB Alliance) is a product development partnership (PDP), working toDocID: 1avZ3 - View Document |
| Critical Path Opportunities Report March 2006 Critical Path Opportunities Report and ListDocID: 12w9D - View Document |
| Translational Safety in Drug Development – Innovations and Challenges A Joint Regional Chapter Meeting with SCCSOT and the Critical Path Institute Accelerating the Path to a Healthier WorldDocID: ZUkW - View Document |
| FDA Co-Sponsorship AgreementsDocID: Zf5j - View Document |